Expert Interviews

At the 29th APAO Symposium, Lifetime Achievement Award honoree Colleen Tetzlaff, PA-C, shared insights on adapting to rapid clinical advancements.

Kelsey Martin, APRN, discusses the tolerability and clinical benefits of frontline antibody-drug conjugates for metastatic TNBC.

Experts at the 2026 APAO Symposium highlighted patient education, clinical trial updates, and professional development in cancer care.

Kennon McCollum explains how psychosocial, physical, and financial barriers impact treatment selection for patients with CLL.

Andrew Evens, DO, and Joanna Rhodes, MD, discuss evolving CLL treatment paradigms, CAR T-cell therapy versus bispecific antibodies, and expanding community access to specialized lymphoma care.

NP Theresa Stukus and NP Nelli Zafman discuss the essential role of comprehensive biomarker testing in guiding individualized treatment decisions for patients with metastatic triple-negative breast cancer (mTNBC).

NP Theresa Stukus and NP Nelli Zafman discuss how recent clinical trial data, updated clinical practice guidelines, and new FDA approvals are influencing frontline treatment decisions for metastatic triple-negative breast cancer (mTNBC).

How oncology nurses can dismantle patient myths, secure early dietitian referrals, and collaborate to optimize supportive care like vitamin D.

Oncology clinical trial nurse navigator Elise Curry, RN, explains the impact of the FDA's approval of oral iberdomide for multiple myeloma.

Oncology NPs discuss new frontline options for metastatic triple-negative breast cancer, using cases to guide therapy choice and manage toxicities.

A social worker explains how patient "difficulties" are often trauma-based fight, flight, freeze, or fawn responses to a health crisis.

Dr. Michael Wong discusses clinical workflows, dosing calculations, and biosafety protocols for the newly approved Tudriqev-nivolumab regimen.

A new study reveals global gaps in integrative oncology knowledge, highlighting communication and the role of APPs in community settings.

New Phase 3 ENDURANCE trial data shows no survival benefit for indefinite lenalidomide maintenance over 2 years in non-transplant myeloma patients.

Theresa Lynne Harrington Stukus, ANPBC NP, discusses managing the influx of new breast cancer therapies and the importance of professional networking.

Oncology nurse Pattie Jakel shares her story of ILC recurrence, highlighting why MRI and specialized education are vital for lobular breast cancer.

Laura Cullen DNP, RN, FAAN discusses leadership and systems infrastructure ahead of her keynote at the Roswell Park Evidence-Based Practice Symposium.

Fumiko Chino, MD, discusses strategies for oncology nurses to address unproven treatments like ivermectin while maintaining patient trust.

Oncology dietitian Gabrielle Raucci explores the role of creatine in cancer care, highlighting when to use it and risks during active treatment.

The FDA has approved perioperative pembrolizumab and enfortumab vedotin for adult patients with muscle-invasive bladder cancer.

In the phase 3 RASolute 302 trial, oral KRAS inhibitor daraxonrasib nearly doubled median overall survival to 13.2 months in pancreatic cancer.

Stephanie Desrosiers discusses strategies for oncology nurses to manage chemotherapy shortages, ensuring patient safety, equity, and mental health.

NYU Langone experts discuss multidisciplinary care, diagnostic challenges, and nursing's role in treating rare bone and soft tissue sarcomas.

Drs. Sledge and Pastorini discuss how AI-powered molecular profiling corrected a misdiagnosis and the vital "early warning" role of oncology nurses.

FDA approves gedatolisib for HR+/HER2– breast cancer. Learn about the VIKTORIA-1 trial, dosing, and nursing strategies for managing stomatitis.

FDA approves SC isatuximab-irfc with the CirCLIQ on-body injector, streamlining multiple myeloma care and reducing nursing burden.

Donna Berizzi discusses how LeanTaaS capacity management tools reduce nurse burnout by optimizing outpatient workflows and improving patient access.

Dr. Rodney Haring discusses the 2026 AACR Cancer Disparities Report and the critical role of oncology navigators in tribal and rural health equity.